Skip to main content

Table 4 Predictors for upgrade to ductal carcinoma in situ (DCIS) with invasive component (IC) in pre-operative biopsy diagnosed DCIS patients

From: Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

N = 682

Post-OP pure DCIS (N = 449)

Post-OP upgrade to DCIS-IC (N = 233)

P value

Age, year

52 ± 9.8

52.9 ± 10.8

0.29

Location

  

0.62

Right

219(48.8)

109(46.8)

 

Left

230(51.2)

124(53.2)

 

Biopsy method

N/A = 2

N/A = 1

 < 0.01

CNB

233(52.1)

188(81)

 

Stereotactic biopsy

140(31.3)

27(11.6)

 

Excisional biopsy

71(15.9)

17(7.3)

 

MMG

3(0.7)

0(0)

 

Sonogram tumor size, cm

1.9 ± 1.1

2.2 ± 1.2

 < 0.01

Mammogram tumor size, cm

2.4 ± 1.3

2.8 ± 1.1

0.14

MRI tumor size, cm

3.6 ± 2.2

4.5 ± 2.1

 < 0.01

Pathology tumor sizea, cm

2.7 ± 2.7

1.4 ± 1.9

 < 0.01

Gross tumor sizeb, cm

3.3 ± 2.4

3.8 ± 2.4

0.02

Stage (N/A = 33)

N/A = 31

N/A = 2

 < 0.01

0

381(91.1)

9(3.9)

 

I

26(6.2)

157(68.0)

 

II

10(2.4)

55(23.8)

 

III

1(0.2)

10(4.3)

 

Grade (N/A = 74)

N/A = 44

N/A = 30

 < 0.01

I

28(6.9)

48(23.6)

 

II

211(52.1)

126(62.1)

 

III

166(41.0)

29(14.3)

 

ER

N/A = 24

 

 < 0.01

Positive

335(78.8)

149(63.9)

 

Negative

90(21.2)

84(36.1)

 

PR (N/A = 33)

N/A = 33

 

 < 0.01

Positive

303(72.8)

135(57.9)

 

Negative

113(27.2)

98(42.1)

 

HER-2 (N/A = 203)

N/A = 199

N/A = 4

0.25

Positive

99(39.6)

79(34.5)

 

Negative

151(60.4)

150(65.5)

 

MRI LN metastasis

N/A = 184

N/A = 91

0.01

Yes

50(18.9)

44(31.0)

 

No

215(81.1)

98(69.0)

 

Lymph node stage

N/A = 61

N/A = 22

 < 0.01

N0

385(99.2)

164(77.7)

 

N1

2(0.5)

38(18.0)

 

N2

0(0)

7(3.3)

 

N3

1(0.3)

2(0.9)

 

OP method

  

 < 0.01

Total

255(56.8)

175(75.1)

 

Partial

194(43.2)

58(24.9)

 

LN meta

N/A = 30

N/A = 3

 < 0.01

Yes

3(0.7)

46(20.0)

 

No

416(99.3)

184(80.0)

 

Method_LN

  

 < 0.01

SLNB

365(81.3)

163(70.0)

 

SLNB + ALND

14(3.1)

35(15.0)

 

ALND

18(4.0)

25(10.7)

 

ND

52(11.6)

10(4.3)

 
  1. MMG mammography-guided biopsy, LN lymph node, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, ND not done, OP operation, DCIS ductal carcinoma in situ, TNBC triple negative breast cancer, ER estrogen receptor, PR progesterone receptor, HER-2 human epithelial grow receptor type 2, N/A not available
  2. aPathology tumor size: in pure DCIS cases pathologic tumor size=DCIS tumor size, if containing invasive component then pathologic tumor size=invasive cancer tumor size,
  3. bGross tumor size: invasive + non-invasive component tumor size